- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
NCI mulls genetic risk of prostate, breast cancer
Future cancer management may rely on identifying healthy individuals at risk before they develop symptoms of disease, according to National Cancer Institute researchers.
Future cancer management may rely on identifying healthy individuals at risk before they develop symptoms of disease, according to National Cancer Institute researchers.
The NCI has launched an initiative to identify genetic alterations that create susceptibility to prostate and breast cancer. The three-year, $14 million Cancer Genetic Markers of Susceptibility project will begin by scanning 2500 genetic samples from men who have been diagnosed with prostate cancer as well as a control group. Data will be available via the NCI.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
